Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml
Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml is a medicine authorised by Swissmedic under authorisation number 65041. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 12 September 2014 and the authorisation is valid without a time limit. ATC code A10AE56 places the medicine in the group Drugs used in diabetes.
| Authorisation number | 65041 |
|---|---|
| Name | Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml |
| Full name | Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml, Injektionslösung |
| Authorisation holder | Novo Nordisk Pharma AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | A10AE56 |
| First authorisation | 12 September 2014 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml, Injektionslösung | B | 12 September 2014 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 5 | 3 x 3 | ml | A10AE56 | 07.06. | B |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml authorised in Switzerland?
Yes. Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml is authorised by Swissmedic under authorisation number 65041, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml have?
Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Xultophy Insulin Degludec 100 E/ml und Liraglutide 3.6 mg/ml?
The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.